Healthcare
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
The bill may lead to a 15% to 25% reduction in expected returns for drugs in the top quintile of expected returns. Meaning a decrease in new medications entering the market in the following years.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
“You are not a horse. You are not a cow. Seriously, y’all. Stop it.” This is the FDA’s recently tweeted advice to Americans seeking out alternative, unapproved treatments for COVID-19.
It was another busy week in clinical trial news. Here’s a look.
As governments and now even businesses push citizens to get vaccinated against COVID-19, anti-vaxxers are loading up more ammo for their argument with this week’s report.
Cerner has appointed former Google Health boss David Feinberg as its new chief executive and president effective October 1, 2021.
Fueled by the highly contagious delta variant, life science companies have issued policies on COVID-19 vaccines, including verbiage around exemptions or solutions for medical objections.
PRESS RELEASES